A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells

For Huntington’s disease (HD) cell-based therapy, the transplanted cells are required to be committed to a neuronal cell lineage, survive and maintain this phenotype to ensure their safe transplantation in the brain. We first investigated the role of RE-1 silencing transcription factor (REST) inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: André, Emilie M., Delcroix, Gaëtan J., Kandalam, Saikrishna, Sindji, Laurence, Montero-Menei, Claudia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835496/
https://www.ncbi.nlm.nih.gov/pubmed/31614758
http://dx.doi.org/10.3390/pharmaceutics11100526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835496/
https://www.ncbi.nlm.nih.gov/pubmed/31614758
http://dx.doi.org/10.3390/pharmaceutics11100526

Ejemplares similares